Fig. 1. Identification of HLA-A24-restricted, Eps8-derived peptides.

a Docked complex of HLA-A24 protein and a candidate peptide. PyMol (Molecular Graphics System) software was used to visualize this model. b Results for the free energy prediction. c Eps8 peptide-reactive CTLs were generated from HLA-A24+ prostate cancer patients. After three rounds of in vitro peptide stimulation (10 μM), peptide-sensitized PBMCs were examined by an ELISPOT assay using K562 or K562/A24 cells pulsed with corresponding peptide. The cells were cultured in triplicate. d Peptide-specific CTLs were generated from HLA-A*1101/2402+ HD.1, HLA-A*0207/2402+ HD.2, and HLA-A*1101/2402+ HD.3. The number of IFN-γ-producing CTLs was analyzed by ELISPOT assay. e Eps8-specific CD8+ T cells were measured using the PE-labeled HLA-A*2402/Eps8 tetramer along with APC-labeled anti-CD3 and FITC-labeled anti-CD8 mAbs